Product Description: Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC50 of 0.2 nM-3.5 nM[1]. Asunaprevir inhibits SARS-CoV-2 3CLpro activity[5].
Applications: COVID-19-anti-virus
Formula: C35H46ClN5O9S
References: [1]Pelosi LA, et al. Effect on HCV Replication by Combinations of Direct Acting Antivirals Including NS5A Inhibitor BMS-790052.
Antimicrob Agents Chemother. 2012 Jul 30./[2]McPhee F, et al. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).
Antimicrob Agents Chemother. 2012 Aug 6./[3]McPhee F, et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.
Antimicrob Agents Chemother. 2012 Jul;56(7):3670-81./[4]Pasquinelli C, et al. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.
Antimicrob Agents Chemother. 2012 Apr;56(4):1838-44./[5]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.
CAS Number: 630420-16-5
Molecular Weight: 748.29
Compound Purity: 99.84
Research Area: Infection
Solubility: DMSO : ≥ 100 mg/mL/Ethanol : 20 mg/mL (ultrasonic)
Target: HCV;HCV Protease;SARS-CoV
English
Deutsch
